Home Financing StockWatch: Vertex Bucks Bear Market with Boston Expansion, CF Growth

Vertex_Drydock Ave_exterior-2_750xx4578-2575-211-0 — Vertex Pharmaceuticals says it plans to base about 500 additional employees at 344,000-square-foot 20-22 Drydock Ave. (pictured), which the company will build in Boston’s Seaport District, near its newly-dedicated Jeffrey Leiden Center for Cell and Genetic Therapies. [Related Beal]

StockWatch: Vertex Bucks Bear Market with Boston Expansion, CF Growth

Chimerix plunges on DSTAT halt; Idera jumps as successful trial ends early; Keros drops on Phase I data release

By Alex Philippidis

May 19, 2022

Vertex Pharmaceuticals says it plans to base about 500 additional employees at 344,000-square-foot 20-22 Drydock Ave. (pictured), which the company will build in Boston’s Seaport District, near its newly-dedicated Jeffrey Leiden Center for Cell and Genetic Therapies. [Related Beal]

Another factor in Vertex’s stock rising this week relates to its collaborations with Moderna, including partnerships to discover and develop mRNA therapies for cystic fibrosis (CF), as well as to discover and develop inhalable lipid nanoparticles (LNPs) to deliver those therapies. Moderna is partnering with Vertex on two parallel approaches for addressing the unmet need to deliver CF treatments to the approximately 5,000 CF patients who do not produce any CFTR protein . . .